Novartis AG with ticker code (NVS) have now 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 107 and 102 and has a mean target at 104.25. Now with the previous closing price of 92.81 this would indicate that there is a potential upside of 12.3%. There is a 50 day moving average of 89.97 and the 200 day MA is 85.34. The market cap for the company is $193,849m. Find out more information at: https://www.novartis.com
The potential market cap would be $217,743m based on the market concensus.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
